Amgen

Open: 258.68 Close: 256.71 Change: -1.97

16 risks of investing in Amgen found by an AI after reading the whole internet.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, FTC, Therapeutics, acquisition, lawsuit, Federal, and the most common words in the summary are: amgen, horizon, job, ftc, therapeutic, news, drug, . One of the sentences in the summary was: FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics. Other searches related …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics. FTC had filed a lawsuit in May seeking to block the acquisition over concerns it would allow Amgen to leverage its drug portfolio.

Today's News

Amgen and Horizon Therapeutics have reached a consent order agreement with the Federal Trade Commission (FTC) to resolve an ongoing administrative lawsuit. This sets the stage for Amgen to proceed with the last steps in finalising the acquisition of Horizon. Amgen reached an agreement to acquire Horizon in December last year. FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics. Deal resolves lawsuit the FTC filed in May seeking to block the acquisition over concerns it would allow Amgen to leverage its drug portfolio to stifle competition in pharmaceutical industry. Amgen/Horizon Therapeutics currently carry a Zacks Rank #3 (Hold) each. FTC suspends challenge to Amgen-Horizon Therapeutics deal. FTC had filed a lawsuit in May seeking to block the acquisition, arguing that the deal would stifle competition in the pharmaceutical industry. Amgen North Carolina (ANC) will be an Associate in the manufacturing organization at the companys Holly Springs, NC start date Aug 29, 2023. Amgen unveiled Phase II clinical data for Olpasiran, a small interfering RNA (siRNA) that is being developed to reduce Lp(a) in patients with cardiovascular disease (CVD) The Federal Trade Commission (FTC) will allow Amgen to continue a $27.8 billion purchase of Horizon Therapeutics. Amgen is a leader in biotechnology-based human therapeutics. Amgen expects to complete the Horizon acquisition before 2023-end. FTC has put a pause on its lawsuit against Thousand Oaks-based Amgens acquisition of Horizon Therapeutics to allow time for the FTC to consider a settlement. The FTCs concern was that, by acquiring these products, Amgen would stifle competition. Federal Trade Commission suspends challenge of Amgens purchase of Horizon Therapeutics. FTC has settled on a proposed consent order with Amgen Inc. to address the potential competitive harm Amgen could bring. Amgen on Friday said it will renounce and future sales tactics. Amgen and Horizon Therapeutics plc resolve ftc lawsuit, clearing path to close acquisition. FTC settlement with Amgen could influence M&A deals in pharmaceutical space. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen was named one of Americas Greatest Workplaces by Newsweek. Federal Trade Commission drops lawsuit to block Amgens $28 billion deal to acquire Horizon Therapeutics. FTC said settlement would prevent “potential competitive harm’ Amgen is an Equal Opportunity Employer and will consider you without regard to race, colour, religion, sex, sexual orientation, gender identity, national origin, protected veteran status or disability status. Federal Trade Commission reached a proposed consent order with Amgen Inc. to address the potential competitive harm that would result from Amgens $27.8 billion acquisition of Horizon Therapeutics plc. Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, FTC, Therapeutics, acquisition, lawsuit, Federal, and the most common words in the summary are: amgen, horizon, job, ftc, therapeutic, news, drug, . One of the sentences in the summary was: FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #horizon #job #ftc #therapeutic #news #drug.